OraSure Technologies Appoints Mara G. Aspinall to Board of Directors
June 22 2017 - 6:00AM
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, today announced
the appointment of Ms. Mara G. Aspinall as a member of the
Company's Board of Directors. Ms. Aspinall will serve as a
Class II Director with an initial term expiring at the Company’s
2020 Annual Meeting of Stockholders. She will also serve on
the Audit and Compensation Committees of the Board.
"We are pleased to welcome Mara as a new member
of the Company’s Board of Directors," said Stephen S. Tang, Ph.D.,
Chairman of the OraSure Technologies Board of Directors.
"Mara’s executive leadership and extensive background in life
sciences, especially in the molecular and diagnostics fields, make
her an ideal addition to our Board. This is an exciting time
for OraSure and I am confident that Mara will be a valuable
contributor as the Company continues to grow and execute against
its strategic priorities."
Ms. Aspinall currently serves as the President
and CEO of Health Catalysts, an investment and advisory firm that
focuses on growth of early stage life science and technology
companies. She also currently serves as the Executive
Chairman of GenePeeks, a computational genomics company offering
proprietary technology to help identify the pre-conception risk of
passing on monogenic disease to progeny.
Prior to these positions, Ms. Aspinall served as
President and CEO, Global Head of Roche Tissue Diagnostics, where
she led Ventana Medical Systems, a division of the Roche Group that
provides tissue-based cancer diagnostic instruments, products and
services. Prior to that she founded and served as CEO and
Director of On-Q-ity, Inc., a diagnostic research company focused
on improving cancer treatment through the capture of circulating
tumor cells in a patient’s blood. Ms. Aspinall also spent 12
years with Genzyme Corporation, serving as President of the Genzyme
Genetics division, a leading provider of esoteric and genetic tests
for the reproductive, oncology and personalized medicine markets,
and as President of the Genzyme Pharmaceuticals division, a custom
pharmaceutical intermediates provider. Ms. Aspinall began her
career as a management consultant with Bain & Company.
Ms. Aspinall co-founded the International School
of Biomedical Diagnostics at Arizona State University, the first
school dedicated to diagnostics as an independent discipline.
In addition, she has taught in the area of diagnostics at the
University of Arizona School of Medicine, Harvard Medical School
and Boston University School of Management, and is a frequent
national speaker on healthcare related issues.
Ms. Aspinall is a member of the Harvard Business
School Healthcare Initiative Advisory Board, was recognized as
Arizona BioSciences (“AZBio”) Leader of the Year in 2016 and has
authored a number of articles for health-care industry
publications. In addition to her Board service at GenePeeks,
Ms. Aspinall currently serves on the Boards of Abcam Plc (AIM:ABC)
and Allscripts (NASDAQ:MDRX), and has served on various councils
and boards of organizations within her community for the past
decade.
Ms. Aspinall holds an M.B.A. from Harvard
Business School and a B.A. in International Relations from Tufts
University.
About OraSure
Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health.
For more information on OraSure Technologies,
please visit www.orasure.com.
Company contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
Investorinfo@orasure.com
www.orasure.com
Shauna White
Corporate Marketing Manager
484-353-1575
media@orasure.com
www.orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Sep 2023 to Sep 2024